Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival-Reference-Cited by-同舟云学术

Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival

Published:2020-08-24 Issue: Volume:Publish Ahead of Print Page:
ISSN:1541-2016
Container-title:Applied Immunohistochemistry & Molecular Morphology
language:en
Short-container-title:

Author:

Zito Marino Federica,Baselice Simona,Erra Stefania,Ronchi Andrea,Montella Marco,Morgillo Floriana,Vicidomini Giovanni,Santini Mario,Poziello Giuseppina,Cozzolino Immacolata,Accardo Marina,Franco Renato

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Medical Laboratory Technology,Histology,Pathology and Forensic Medicine

Reference37 articles.

1. Multimodality treatment of malignant pleural mesothelioma;Berzenji;F1000Res,2018

2. Multimodality treatment of pleural mesothelioma;Shersher;Surg Oncol Clin N Am,2013

3. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification;Galateau-Salle;J Thorac Oncol,2016

4. Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group;Husain;Arch Pathol Lab Med,2018

5. Malignant pleural mesothelioma;Tsao;J Clin Oncol,2009

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma;Journal of Personalized Medicine;2022-12-02

2. RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin;BMC Cancer;2021-08-05